About
AKKURE revolutionizes the Pharmaceutical & Hospital industry with a patient-centric platform for smart contract based dynamic consent management of patient’s clinical, genomic and physiological data, creating new assets from public & enterprise data transformed into digital medical twins (DMTs) for continuous real-time access to integrated patient data.
DMTs for pre-clinical Insilico trial models, offer live insights for patient identification, cohort localisation and global site consolidation, incorporating digital and multiomic biomarkers accelerating virtual and precision oncology trials.
Developed in stealth with Microsoft, validated via a commercial pilot focused on breast cancer with a leading EU medical software company accessing 500,000 patient records, endorsed through a multi-year partnership with a top 3 global CRO, and accelerated with a POC with the world's largest EMR provider & hospital network in a nation creating 1 million digital twins, AKKURE is active with EMR and health data providers over 4 continents.
Key pharmaceutical customers, including the aforementioned CRO, show readiness to adopt our innovative approach for securing RWE/RWD access and DMT powered Insilico precision trial matching.
Embracing opportunities for patient-owned health data democratization and secondary use and access via the US 21st Century Cures Act and EU's 2024 Health Data Space legislation, AKKURE transforms new and existing health data into a foundational digital infrastructure for a global precision trials/therapeutics market.
DATA ANALYSIS FOR STRATEGIC DECISIONS